These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 18207665)
1. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Eade TN; Horwitz EM; Ruth K; Buyyounouski MK; D'Ambrosio DJ; Feigenberg SJ; Chen DY; Pollack A Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):338-45. PubMed ID: 18207665 [TBL] [Abstract][Full Text] [Related]
2. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662 [TBL] [Abstract][Full Text] [Related]
3. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858 [TBL] [Abstract][Full Text] [Related]
4. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587 [TBL] [Abstract][Full Text] [Related]
5. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069 [TBL] [Abstract][Full Text] [Related]
6. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192 [TBL] [Abstract][Full Text] [Related]
7. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807 [TBL] [Abstract][Full Text] [Related]
8. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091 [TBL] [Abstract][Full Text] [Related]
10. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Liauw SL; Weichselbaum RR; Rash C; Correa D; Al-Hallaq HA; Pelizzari CA; Jani AB Technol Cancer Res Treat; 2009 Jun; 8(3):201-6. PubMed ID: 19445537 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627 [TBL] [Abstract][Full Text] [Related]
12. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725 [TBL] [Abstract][Full Text] [Related]
13. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452 [TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170 [TBL] [Abstract][Full Text] [Related]
15. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Kalakota K; Liauw SL Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863 [TBL] [Abstract][Full Text] [Related]
16. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580 [TBL] [Abstract][Full Text] [Related]